Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma

MT NewswiresDec 16, 2024 08:05 ET

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

BenzingaDec 16, 2024 07:15 ET

Express News | EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma

BenzingaDec 16, 2024 07:15 ET

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

SoligenixDec 16, 2024 00:00 ET

Soligenix Announces Analysis From Protocol HPN-CTCL-04

TipRanksDec 2, 2024 07:40 ET

Express News | Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual...

BenzingaDec 2, 2024 07:40 ET